A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

ClinicalTrials.gov ID: NCT02473952

Public ClinicalTrials.gov record NCT02473952. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis

Study identification

NCT ID: NCT02473952
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Grifols Therapeutics LLC; Industry
Enrollment: 62 participants

Conditions and interventions

Conditions

Myasthenia Gravis, Generalized

Interventions

IGIV-C Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 85 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 31, 2015
Primary completion: Dec 31, 2017
Completion: Dec 31, 2017
Last update posted: Mar 4, 2019

2015 – 2018

United States locations

U.S. sites: 15
U.S. states: 14
U.S. cities: 15

Facility	City	State	ZIP	Site status
Phoenix Neurological Associates, Ltd.	Phoenix	Arizona	85018	—
University of California-Irvine	Orange	California	92868	—
Yale University School of Medicine	New Haven	Connecticut	06510	—
University of Florida Health Science Center	Jacksonville	Florida	32209	—
University of South Florida	Tampa	Florida	33612	—
Georgia Regents University	Augusta	Georgia	30912	—
Indiana University	Indianapolis	Indiana	46202	—
University of Kansas Medical Center Research Institute, Inc.	Kansas City	Kansas	66160	—
Rutgers New Jersey Medical School	Newark	New Jersey	07103	—
Columbia University Medical Center	New York	New York	10032	—
Ohio State University Wexner Medical Center	Columbus	Ohio	43220	—
Thomas Jefferson University Hospital	Philadelphia	Pennsylvania	19107	—
Houston Methodist Neurological Institute	Houston	Texas	77030	—
University of Vermont Medical Center	Burlington	Vermont	05405	—
University of Washington Medical Center	Seattle	Washington	98195	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02473952, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 4, 2019 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02473952 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →